We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | NASDAQ:RIGL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 6.09% | 1.22 | 0.705 | 2.09 | 1.22 | 1.16 | 1.18 | 791,587 | 05:00:06 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Rigel Pharmaceuticals Inc. rose more than 15% Thursday after the clinical-stage biotechnology company inked a licensing and collaboration agreement with drug giant Eli Lilly & Co.
The agreement provides up to $960 million in up-front and potential milestone payments to Rigel, along with royalties on sales.
Under the agreement, Eli Lilly gets an exclusive worldwide license to Rigel's receptor-interacting serine/threonine-protein kinase 1, or RIPK1, inhibitors, including the Phase 2-ready molecule R552, in all indications.
Shares of Rigel, which had roughly $57.3 million in cash, cash equivalents and short-term investments at the end of 2020, were recently up about 18%, to $5.33, after reaching a 52-week high of $5.50 earlier in the session.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 18, 2021 10:36 ET (15:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Rigel Pharmaceuticals Chart |
1 Month Rigel Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
